Valuation: Insmed Incorporated

Market Cap 25.7B 22.6B 21.37B 19.38B 36.4B 2,467B 36.62B 256B 98.83B 1,259B 96.48B 94.39B 4,045B P/E 2026 *
-72x
P/E 2027 * 162x
Enterprise Value 25.07B 22.04B 20.85B 18.91B 35.51B 2,406B 35.72B 250B 96.4B 1,228B 94.1B 92.07B 3,945B EV / Sales 2026 *
13.9x
EV / Sales 2027 * 8.53x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
1 week-2.75%
Current month-3.41%
1 month-0.73%
3 months+13.82%
6 months-19.02%
Current year-32.39%
1 week 115.87
Extreme 115.87
122.9
1 month 115.87
Extreme 115.87
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%-2.75%-14.13%+356.79% 25.73B
-0.37%-3.67%+57.21%+87.75% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
+0.75%+0.75%+36.71%+21.09% 27.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-7.59% 20.74B
-1.70%+0.43%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
-2.53%-8.15%-6.38%+483.59% 14.23B
-0.83%-8.40%-26.11%+745.90% 12.45B
Average -0.29%-0.94%+31.09%+225.54% 28.76B
Weighted average by Cap. -0.15%-1.39%+35.35%+154.61%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.5B 1.36B 2.56B 174B 2.58B 18B 6.95B 88.56B 6.79B 6.64B 285B 2.88B 2.53B 2.39B 2.17B 4.07B 276B 4.1B 28.64B 11.06B 141B 10.8B 10.56B 453B
Net income -350M -308M -291M -264M -496M -33.58B -498M -3.48B -1.35B -17.13B -1.31B -1.28B -55.06B 182M 160M 151M 137M 257M 17.43B 259M 1.81B 699M 8.9B 682M 667M 28.59B
Net Debt -632M -556M -525M -477M -895M -60.65B -900M -6.29B -2.43B -30.95B -2.37B -2.32B -99.45B -1.16B -1.02B -962M -872M -1.64B -111B -1.65B -11.52B -4.45B -56.65B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
28/09/26 $117.67 -0.14% 1,744,363
25/09/26 $117.83 -3.06% 2,672,745
24/09/26 $121.55 +2.71% 2,233,624
23/09/26 $118.34 -2.05% 1,921,655
22/09/26 $120.82 -0.15% 2,405,270
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
117.67USD
Average target price
199.04USD
Spread / Average Target
+69.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock